Seyfarth Synopsis: As we reported here, the CBD (cannabidiol) craze is sweeping the nation. By 2022, it is expected to be a $22 billion per year industry. That said, if a CBD product has a concentration of more than 0.3% of tetrahydrocannabinol (THC), an amount generally viewed to be sufficient to produce a psychoactive
Continue Reading Department of Transportation Cautions Employers About CBD Use By Regulated Workers
Weed at Work: Should Employers Expand “Alcohol at Work” to Cover Recreational Cannabis?
By Jennifer L. Mora and Adam R. Young
Seyfarth Synopsis: Employers considering a tolerant attitude towards recreational cannabis in the workplace should consider safety hazards and legal liabilities.
In the heyday of the two-martini lunch, employers regularly tolerated alcohol in the workplace or employees presumably impaired by alcohol returning to work. Over the succeeding decades, employers began to concentrate
Continue Reading Weed at Work: Should Employers Expand “Alcohol at Work” to Cover Recreational Cannabis?
Marijuana Breathalyzers: Could New Testing Methods Help Employers And Employees?
By Anthony Califano, Jennifer Mora, and Frederick T. Smith
Seyfarth Synopsis: Employers are grappling with the wave of marijuana laws sweeping the nation, some of which provide very employee-friendly protections. While no state requires an employer to tolerate employees’ use of marijuana or impairment while they are working, present drug testing methodologies cannot determine whether an employee
Continue Reading Marijuana Breathalyzers: Could New Testing Methods Help Employers And Employees?
CBD Lawsuit Reflects Trucker Termination for THC Tainted Drug Products
By Jennifer L. Mora, Adam R. Young, and Craig B. Simonsen
Seyfarth Synopsis: The Western District of New York, in Horn v. Medical Marijuana, Inc., et al., issued an initial procedural order last week in a case where the plaintiff’s purchase and use of the defendant products resulted in a failed drug test that resulted in his
Continue Reading CBD Lawsuit Reflects Trucker Termination for THC Tainted Drug Products
CBD is Everywhere – But Where Does the FDA Stand?
By Tonya M. Esposito, Renee B. Appel, and Jonathan Huie
Seyfarth Synopsis: CBD is “thriving” in the current regulatory environment, but is it doing so illegally?
As former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb opined last week, “the CBD craze is getting out of hand. The FDA needs to act.” Since the passage
Continue Reading CBD is Everywhere – But Where Does the FDA Stand?
The Stoned Age: What the CBD Craze Means for Employers and Their Substance Abuse Policies
Seyfarth Synopsis: The federal Drug Enforcement Agency (DEA) recently announced that drugs that include CBD (cannabidiol) with less than 0.1% of THC (tetrahydrocannabinols) are now considered Schedule V drugs provided they are approved by the federal Food and Drug Administration (FDA). The move marked the first time the DEA removed any form of cannabis from
Continue Reading The Stoned Age: What the CBD Craze Means for Employers and Their Substance Abuse Policies